July 9, 2014
BU Oncology & Hematology Head Takashi Shindo Bayer Yakuhin plans to make its cancer field products into an additional profit pillar in 2017 and onwards by accelerating the development of its new radioactive therapeutic agent and by expanding the indications...read more